← Back

PathMaker Neurosystems Inc. Announces the Addition of Institute Professor Emilio Bizzi of MIT to its Scientific Advisory Board

Boston, MA and Paris, France (September 13, 2016) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, has named Emilio Bizzi, M.D., Ph.D., to the Company’s Scientific Advisory Board.

Dr. Emilio Bizzi is an Institute Professor at Massachusetts Institute of Technology (MIT), and an Investigator in the McGovern Institute for Brain Research. He brings over 40 years of experience in the neuroscience of motor control, and one of his key discoveries is that groups of muscles are activated in a coordinated fashion through spinal cord neural circuitry.  “I am delighted to be joining PathMaker’s Scientific Advisory Board.  The company’s approach to non-invasively modulating spinal cord excitability using simultaneous stimulation at multiple sites in the nervous system has the potential to open a new chapter in the treatment of patients with chronic neurological conditions.”

Dr. Bizzi earned an M.D. from the University of Rome in 1958 and a Ph.D. from the University of Pisa in 1968. Dr. Bizzi joined the MIT faculty in 1968 and served as director of the Whitaker College of Health Sciences and Technology from 1983 to 1989. Dr. Bizzi chaired the MIT Department of Brain and Cognitive Sciences from 1986 to 1997. He was appointed Investigator at the McGovern Institute in 2001. Among many other honors, Dr. Bizzi became a member of the National Academy of Sciences in 1986, the National  Academy of Medicine  in 2005, and the Accademia dei Lincei (Rome) in 2006.  He received the President of Italy’s Gold Medal for Scientific Contributions in 2005, and he served from 2006-2010 as President of the American Academy of Arts and Sciences.

“We are truly pleased to have Dr. Bizzi and his internationally renowned neuroscience expertise contributing to our Scientific Advisory Board,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “Both his research work and clinical knowledge in the area of motor control will be invaluable as we progress our clinical programs through approval and commercialization.  With our first product now in IRB-approved clinical trials, we are rapidly advancing our new technology based on Coordinated Multi-site Neurostimulation.”

About PathMaker Neurosystems Inc.

PathMaker Neurosystems Inc. is a clinical-stage neurotechnology company developing non-invasive neurotherapy systems based on Coordinated Multi-site Neurostimulation. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market entirely novel, breakthrough approaches to non-invasively treating neuromotor disorders. More than 48 million patients in the US, Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. Visit the company website at www.pmneuro.com.

Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, dgoncalves@tizinc.com